Anne T Berg1,2, Susan R Levy3,4, Francine M Testa3,4. 1. Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois. 2. Department of Pediatrics, Northwestern-Feinberg School of Medicine, Chicago, Illinois. 3. Department of Pediatrics, Yale School of Medicine, New Haven, Connecticut. 4. Department of Neurology, Yale School of Medicine, New Haven, Connecticut.
Abstract
OBJECTIVES: Developmental encephalopathic epilepsies (DEEs) are characterized by refractory seizures, disability, and early death. Opportunities to improve care and outcomes focus on West syndrome/infantile spasms (WS/IS). Lennox-Gastaut syndrome (LGS) is almost as common but receives little attention. We examined initial presentations of DEEs and their evolution over time to identify risk and indicators of developing LGS. METHODS: Data are from the Connecticut Study of Epilepsy, a prospective, longitudinal study of 613 children with newly diagnosed epilepsy recruited in 1993-1997. Central review of medical records permitted classification of epilepsy syndromes at diagnosis and at reclassification 2, 5, and 9 years later. DEEs were compared to other epilepsies for seizure and cognitive outcomes and mortality. Analyses examined the evolution of DEE syndromes after initial presentation, with specific comparisons made between WS/IS and LGS. Statistical analyses were performed with t tests and chi-square tests. RESULTS: Fifty-eight children (9.4%) had DEEs, median onset age = 1.1 years (interquartile range ([IQR] 0.3-1.3) in DEEs and 6.0 years (IQR 3.0-9.0) in other epilepsies (P < 0.001). DEEs vs other epilepsies had more pharmacoresistance (71% vs 18%), intellectual disability (84% vs 11%), and mortality (21% vs <1%; all P < 0.001). During follow-up, the form of epilepsy evolved in 33 children. WS/IS was the most common initial diagnosis (N = 23) and in 5 children WS/IS evolved later. LGS was diagnosed initially in 4 children (1 later revised) and in 22 by the end of follow-up, including 7 evolving from WS/IS and 12 from nonsyndromic generalized, focal, or undetermined epilepsies. Evolution to LGS took a median of 1.9 years. LGS developed in 13% of infants, including 9% of those who did not present initially with WS/IS. SIGNIFICANCE: DEEs account for disproportionate amounts of pharmacoresistance, disability, and early mortality. LGS often has a window between initial presentation and full expression. LGS should become targeted for early detection and prevention. Wiley Periodicals, Inc.
OBJECTIVES:Developmental encephalopathic epilepsies (DEEs) are characterized by refractory seizures, disability, and early death. Opportunities to improve care and outcomes focus on West syndrome/infantile spasms (WS/IS). Lennox-Gastaut syndrome (LGS) is almost as common but receives little attention. We examined initial presentations of DEEs and their evolution over time to identify risk and indicators of developing LGS. METHODS: Data are from the Connecticut Study of Epilepsy, a prospective, longitudinal study of 613 children with newly diagnosed epilepsy recruited in 1993-1997. Central review of medical records permitted classification of epilepsy syndromes at diagnosis and at reclassification 2, 5, and 9 years later. DEEs were compared to other epilepsies for seizure and cognitive outcomes and mortality. Analyses examined the evolution of DEE syndromes after initial presentation, with specific comparisons made between WS/IS and LGS. Statistical analyses were performed with t tests and chi-square tests. RESULTS: Fifty-eight children (9.4%) had DEEs, median onset age = 1.1 years (interquartile range ([IQR] 0.3-1.3) in DEEs and 6.0 years (IQR 3.0-9.0) in other epilepsies (P < 0.001). DEEs vs other epilepsies had more pharmacoresistance (71% vs 18%), intellectual disability (84% vs 11%), and mortality (21% vs <1%; all P < 0.001). During follow-up, the form of epilepsy evolved in 33 children. WS/IS was the most common initial diagnosis (N = 23) and in 5 childrenWS/IS evolved later. LGS was diagnosed initially in 4 children (1 later revised) and in 22 by the end of follow-up, including 7 evolving from WS/IS and 12 from nonsyndromic generalized, focal, or undetermined epilepsies. Evolution to LGS took a median of 1.9 years. LGS developed in 13% of infants, including 9% of those who did not present initially with WS/IS. SIGNIFICANCE: DEEs account for disproportionate amounts of pharmacoresistance, disability, and early mortality. LGS often has a window between initial presentation and full expression. LGS should become targeted for early detection and prevention. Wiley Periodicals, Inc.
Authors: Yvonne W Wu; Joseph Sullivan; Sharon S McDaniel; Miriam H Meisler; Eileen M Walsh; Sherian Xu Li; Michael W Kuzniewicz Journal: Pediatrics Date: 2015-10-05 Impact factor: 7.124
Authors: Anup D Patel; Anne T Berg; Lori Billinghurst; Daniel Fain; Erin Fecske; Tim Feyma; Zachary Grinspan; Amy Houtrow; Sanjeev Kothare; Gogi Kumar; Erin Lee; Migvis Monduy; Diego Morita; Christina L Szperka; M Cristina Victorio; Ann Yeh; Jeffrey R Buchhalter Journal: Neurology Date: 2017-12-15 Impact factor: 9.910
Authors: Angela Schulz; Temitayo Ajayi; Nicola Specchio; Emily de Los Reyes; Paul Gissen; Douglas Ballon; Jonathan P Dyke; Heather Cahan; Peter Slasor; David Jacoby; Alfried Kohlschütter Journal: N Engl J Med Date: 2018-04-24 Impact factor: 91.245
Authors: Michael Fietz; Moeenaldeen AlSayed; Derek Burke; Jessica Cohen-Pfeffer; Jonathan D Cooper; Lenka Dvořáková; Roberto Giugliani; Emanuela Izzo; Helena Jahnová; Zoltan Lukacs; Sara E Mole; Ines Noher de Halac; David A Pearce; Helena Poupetova; Angela Schulz; Nicola Specchio; Winnie Xin; Nicole Miller Journal: Mol Genet Metab Date: 2016-07-25 Impact factor: 4.797
Authors: Anne T Berg; John T Langfitt; Francine M Testa; Susan R Levy; Francis DiMario; Michael Westerveld; Joseph Kulas Journal: Epilepsia Date: 2007-12-06 Impact factor: 5.864
Authors: Anne T Berg; Gary W Mathern; Richard A Bronen; Robert K Fulbright; Francis DiMario; Francine M Testa; Susan R Levy Journal: Brain Date: 2009-07-28 Impact factor: 13.501
Authors: Anne T Berg; Courtney Wusthoff; Renée A Shellhaas; Tobias Loddenkemper; Zachary M Grinspan; Russell P Saneto; Kelly G Knupp; Anup Patel; Joseph E Sullivan; Eric H Kossoff; Catherine J Chu; Shavonne Massey; Ignacio Valencia; Cynthia Keator; Elaine C Wirrell; Jason Coryell; John J Millichap; William D Gaillard Journal: Epilepsy Behav Date: 2019-06-07 Impact factor: 2.937
Authors: Karen G C B Bindels-de Heus; Sabine E Mous; Maartje Ten Hooven-Radstaake; Bianca M van Iperen-Kolk; Cindy Navis; André B Rietman; Leontine W Ten Hoopen; Alice S Brooks; Ype Elgersma; Henriëtte A Moll; Marie-Claire Y de Wit Journal: Am J Med Genet A Date: 2019-11-15 Impact factor: 2.802
Authors: Souhrid Mukherjee; Thomas A Cassini; Ningning Hu; Tao Yang; Bian Li; Wangzhen Shen; Christopher W Moth; David C Rinker; Jonathan H Sheehan; Joy D Cogan; John H Newman; Rizwan Hamid; Robert L Macdonald; Dan M Roden; Jens Meiler; Georg Kuenze; John A Phillips; John A Capra Journal: HGG Adv Date: 2022-07-19